Published in Can Vet J on May 01, 2006
Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr (1990) 25.24
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest (1990) 10.35
Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet (1993) 2.38
Molecular mechanisms of inherited cardiomyopathies. Physiol Rev (2002) 2.32
Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med (1993) 2.28
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation (1995) 2.25
Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res (1998) 1.98
Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.65
Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation (1995) 1.48
Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47
Familial hypertrophic cardiomyopathy in maine coon cats: an animal model of human disease. Circulation (1999) 1.28
Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation (1995) 1.26
Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. Circulation (1995) 1.11
Comparison of morphologic findings in spontaneously occurring hypertrophic cardiomyopathy in humans, cats and dogs. Am J Cardiol (1993) 1.11
Risk factors, clinical signs, and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy: 74 cases (1985-1989). J Am Vet Med Assoc (1992) 1.06
Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation (1983) 1.05
Cross-sectional echocardiography. I. Analysis of mathematic models for quantifying mass of the left ventricle in dogs. Circulation (1979) 1.03
Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol (1998) 1.00
The genetics of hypertrophic cardiomyopathy. Ann Intern Med (1986) 0.99
Mutations in cardiac myosin heavy chain genes cause familial hypertrophic cardiomyopathy. Mol Biol Med (1991) 0.97
Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation (1993) 0.95
Cardiac renin-angiotensin system. Molecular and functional aspects. Am J Med (1988) 0.93
Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure. Eur Heart J (1994) 0.90
Expression of renin and angiotensin-converting enzyme in human hearts. Heart Vessels (1995) 0.89
Endogenous tissue renin-angiotensin systems. From molecular biology to therapy. Am J Med (1988) 0.88
Plasma taurine concentrations and M-mode echocardiographic measures in healthy cats and in cats with dilated cardiomyopathy. J Vet Intern Med (1991) 0.85
Pulsed Doppler assessment of left ventricular diastolic function in normal and cardiomyopathic cats. J Am Anim Hosp Assoc (1999) 0.84
Paracrine actions of cardiac fibroblasts on cardiomyocytes: implications for the cardiac renin-angiotensin system. Am J Cardiol (1999) 0.84
Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation (1998) 0.81
Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. J Cardiovasc Pharmacol (1999) 0.80
Detection of a pseudonormal mitral inflow pattern: an echocardiographic and tissue Doppler study. Echocardiography (2003) 0.80
Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl. J Vet Pharmacol Ther (1999) 0.79
Protein kinase C in angiotensin II signalling in neonatal rat cardiac fibroblasts. Role in the mitogenic response. Ann N Y Acad Sci (1995) 0.78
Comparison between invasive hemodynamic measurements and noninvasive assessment of left ventricular diastolic function by use of Doppler echocardiography in healthy anesthetized cats. Am J Vet Res (2003) 0.78
Validation of in vivo two-dimensional echocardiographic dimension measurements using myocardial mass estimates in dogs. Am Heart J (1987) 0.77
Estimation of left ventricular mass in conscious dogs. Am J Physiol (1986) 0.77
Hypertrophic cardiomyopathy in a litter of five mixed-breed cats. J Am Anim Hosp Assoc (1999) 0.77
Effects of benazepril in the treatment of feline hypertrophic cardiomyopathy Results of a prospective, open-label, multicenter clinical trial. J Vet Cardiol (1999) 0.77
Different pathophysiology of cardiac hypertrophy in hypertension and hypertrophic cardiomyopathy. J Mol Cell Cardiol (1997) 0.77
Clinical assessment of left ventricular relaxation. J Vet Intern Med (1999) 0.76
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR. Acta Pharmacol Sin (2000) 0.76
Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. J Vet Intern Med (1997) 0.76
The use of enalapril in the treatment of feline hypertrophic cardiomyopathy. J Am Anim Hosp Assoc (1998) 0.76
A cardiovascular monitoring system in conscious cynomolgus monkeys for regulatory safety pharmacology. Part 1: Non-pharmacological validation. J Pharmacol Toxicol Methods (2007) 0.81